세계의 요실금 장치 시장 : 제품별, 요실금 유형별, 환자 유형별, 최종사용자별, 지역별 - 예측(-2030년)

The global Urinary incontinence devices market is projected to reach USD 7.97 billion by 2030 from USD 4.22 billion in 2024, at a CAGR of 11.2% during the forecast period.

This is due to growing attention to personal hygiene and advancements in home healthcare solutions. Additionally, rapid urbanization and rising disposable income, consequently increasing the demand for the urinary incontinence devices. However, the potential side-effects & complications by using urinary incontinence devices such as catheters are the major restraint to the market. Additionally, the use of alternative treatment options to treat urinary icnotinence is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2024-2030.

"The stress incontinence segment of urinary incontinence devices market by incontinence type to hold largest position forecast period."

Based on the incontinence type, the urinary incontinence devices market is divided into stress incontinence, urge incontinence, mixed incontinence, overflow incontinence, and functional incontinence. Among these, in 2023 stress incontinence segment account for the largest market share of XX% in urinary incontinence devices market. Factors driving the growth of stress incontinence segment include rising aging population, which increases the prevalence of pelvic floor dysfunction, particularly among postmenopausal women. The growing prevalence of stress incontinence is driving demand for urinary incontinence devices, including urinary catheters, vaginal & urethral slings, artificial urinary sphincters, electrical stimulation devices are among the others. According to National Center for Biotechnology Information (NCBI), stress urinary incontinence (SUI) is the most reported type, accounting for 37.5% of cases. This significant prevalence highlights the growing demand for urinary incontinence devices.

"The female patients segment accounts for the largest market share in urinary incontinence devices market."

Based on patient type, the urinary incontinence devices market is segmented into male patients and female patients. The female patients segment accounts for the largest market share in urinary incontinence devices market. Women are more prone to incontinence than men, owing to factors such as pregnancy, childbirth, and menopause. During each of these events, women can face bladder control issues. Pregnancy can be a short-term cause of incontinence and bladder control issues. Some women experience incontinence after delivery because of the strain childbirth takes on the pelvic floor muscles. During menopause, the decreasing level of estrogen affects bladder control. However, the prevalence of incontinence is known to increase with age, with up to 75% of women above 65 years reporting an episode of incontinence such as urine leakage, further strengthens market demand for urinary incontinence devices among this segment.

"North America accounted for the second largest share of the urinary incontinence devices market by region."

The global urinary incontinence devices market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Urinary incontinence devices market in North America is the second-largest regional market. This is due to the growing geriatric population along with rising prevalence of urinary incontinence as well as rapid advancement of healthcare infrastructure. The industry has long been established in the area, with high early-stage support and adoption by clinicians for research and emerging technologies. It is characterized by significant market penetration of urinary incontinence devices among key end users. However, the population of North America was approximately 375 million in 2023, with 66.8 million people aged 65 and above, a demographic that is particularly at risk of urinary incontinence. Such factors create a favorable environment for the growth of the urinary incontinence devices market in this region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%
• By Designation: C-level-27%, Director-level-18% and Others-55%
• By Region: Europe-35%, North America-30%, Asia Pacific-22%, Latin America- 10%, and Middle east and Africa - 3%

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the urinary incontinence devices market are Coloplast Corp (Denmark), B. Braun SE (Germany), Johnson & Johnson Services, Inc. (US), Convatec Inc. (UK), Boston Scientific Corporation (US), Hollister Incorporated (US), Becton, Dickinson and Company (BD) (US), Cook Group (US), Cardinal Health (US), Laborie (US), Medtronic (Ireland), and Teleflex Incorporated (US).

Research Coverage

This report studies the urinary incontinence devices market based on product, incontinence type, patient type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

• Analysis of Key divers (Rising prevalence of urinary incontinence, Expanding geriatric population, Growing attention to personal hygiene, and Advancements in home healthcare solutions), restraints (Social stigma associate with incontinence care products, Environmental concerns related to disposal of urinary incontinence products, and Potential side-effects & complications), Challenge (Use of alternative treatment options), opportunity (Technological advancements in urinary incontinence devices and Rapid urbanization and rising disposable income)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the urinary incontinence devices market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches & product approvals in the urinary incontinence devices market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the urinary incontinence devices market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources for secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Company revenue estimation approach
      • 2.2.1.1.1 Presentations of companies and primary interviews
      • 2.2.1.1.2 Primary interviews
      • 2.2.1.1.3 US-based approach
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 ASSUMPTIONS
  • 2.5.1 STUDY ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 URINARY INCONTINENCE DEVICES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: URINARY INCONTINENCE DEVICES MARKET, BY PRODUCT & COUNTRY (2023)
• 4.3 GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 REGIONAL MIX: URINARY INCONTINENCE DEVICES MARKET, 2024 VS. 2030
• 4.5 URINARY INCONTINENCE DEVICES MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of urinary incontinence
    • 5.2.1.2 Expanding geriatric population
    • 5.2.1.3 Growing attention to personal hygiene
    • 5.2.1.4 Advancements in home healthcare solutions
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Social stigma associated with incontinence care products
    • 5.2.2.2 Environmental concerns related to disposal of urinary incontinence products
    • 5.2.2.3 Potential side-effects & complications
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements in urinary incontinence devices
    • 5.2.3.2 Rapid urbanization and rising disposable income
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Use of alternative treatment options
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.3.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF BUYERS
  • 5.7.4 BARGAINING POWER OF SUPPLIERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 KEY BUYING CRITERIA
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.2 REGULATORY FRAMEWORK
    • 5.9.2.1 North America
      • 5.9.2.1.1 US
      • 5.9.2.1.2 Canada
    • 5.9.2.2 Europe
    • 5.9.2.3 Asia Pacific
      • 5.9.2.3.1 China
      • 5.9.2.3.2 Japan
      • 5.9.2.3.3 India
    • 5.9.2.4 Latin America
      • 5.9.2.4.1 Brazil
      • 5.9.2.4.2 Mexico
    • 5.9.2.5 Middle East
    • 5.9.2.6 Africa
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA FOR HS CODE 901839
  • 5.10.2 EXPORT DATA FOR HS CODE 901839
• 5.11 PATENT ANALYSIS
  • 5.11.1 LIST OF MAJOR PATENTS
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 TECHNOLOGY ANALYSIS
  • 5.14.1 KEY TECHNOLOGIES
    • 5.14.1.1 Surgical & implantable devices
  • 5.14.2 COMPLEMENTARY TECHNOLOGIES
    • 5.14.2.1 Electrical stimulation devices
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF AI/GEN AI ON URINARY INCONTINENCE DEVICES MARKET
  • 5.16.1 AI USE CASES

6 URINARY INCONTINENCE DEVICES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 URINARY CATHETERS
  • 6.2.1 INTERMITTENT CATHETERS
    • 6.2.1.1 Reduced risk of infections to boost market
  • 6.2.2 INDWELLING CATHETERS
    • 6.2.2.1 Rising usage by critically ill patients to drive demand
  • 6.2.3 EXTERNAL CATHETERS
    • 6.2.3.1 Ease of use to boost market growth
• 6.3 VAGINAL & URETHRAL SLINGS
  • 6.3.1 RISING PREVALENCE OF STRESS INCONTINENCE TO DRIVE GROWTH
• 6.4 ELECTRICAL STIMULATION DEVICES
  • 6.4.1 GROWING PREFERENCE FOR ELECTRICAL STIMULATION DEVICES FOR TREATMENT OF OAB TO DRIVE GROWTH
• 6.5 ARTIFICIAL URINARY SPHINCTERS
  • 6.5.1 REDUCED RISK OF INFECTIONS ASSOCIATED WITH ARTIFICIAL URINARY SPHINCTERS TO DRIVE ADOPTION
• 6.6 OTHER URINARY INCONTINENCE DEVICES

7 URINARY INCONTINENCE DEVICES MARKET, BY INCONTINENCE TYPE

• 7.1 INTRODUCTION
• 7.2 STRESS INCONTINENCE
  • 7.2.1 GROWING PREVALENCE OF STRESS INCONTINENCE TO DRIVE MARKET GROWTH
• 7.3 URGE INCONTINENCE
  • 7.3.1 CONTINUOUS INNOVATIONS TO SUSTAIN MARKET GROWTH
• 7.4 MIXED INCONTINENCE
  • 7.4.1 GROWING AWARENESS AMONG BOTH PATIENTS AND HEALTHCARE PROVIDERS TO BOOST MARKET GROWTH
• 7.5 OVERFLOW INCONTINENCE
  • 7.5.1 AGING POPULATION AND ASSOCIATED UROLOGICAL CONDITIONS TO DRIVE MARKET DEMAND
• 7.6 FUNCTIONAL INCONTINENCE
  • 7.6.1 MOBILITY DISORDERS TO SUSTAIN MARKET GROWTH

8 URINARY INCONTINENCE DEVICES MARKET, BY PATIENT TYPE

• 8.1 INTRODUCTION
• 8.2 FEMALE PATIENTS
  • 8.2.1 HIGHER RATE OF URINARY INCONTINENCE IN FEMALES TO DRIVE MARKET
• 8.3 MALE PATIENTS
  • 8.3.1 RISING PREVALENCE OF BPH TO PROPEL MARKET GROWTH

9 URINARY INCONTINENCE DEVICES MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 LARGE VOLUME OF SURGICAL PROCEDURES TO DRIVE GROWTH
• 9.3 PHYSICIANS' OFFICES
  • 9.3.1 EXPERTISE OF PROFESSIONALS IN TREATMENT OF URINARY INCONTINENCE TO PROPEL GROWTH
• 9.4 OTHER END USERS

10 URINARY INCONTINENCE DEVICES MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Favorable healthcare initiatives for prevention of UI to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Increasing geriatric population to drive market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Rising healthcare expenditure to propel market
  • 10.3.3 UK
    • 10.3.3.1 Rising prevalence of chronic diseases to support market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Large target population to boost demand
  • 10.3.5 ITALY
    • 10.3.5.1 Rising geriatric population and subsequent rise in UI to drive market
  • 10.3.6 SPAIN
    • 10.3.6.1 Uptake of advanced technologies for UI treatment to support market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Growing focus on preventive care due to large target patient pool to boost demand
  • 10.4.3 JAPAN
    • 10.4.3.1 Presence of established healthcare system and favorable reimbursements to drive market
  • 10.4.4 INDIA
    • 10.4.4.1 Rising cases of urinary incontinence and increasing healthcare investments to propel market
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Favorable reimbursement scenario for medical device manufacturers to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Rising demand for advanced UI products to drive market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN URINARY INCONTINENCE DEVICES MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Product footprint
    • 11.5.5.4 Patient type footprint
    • 11.5.5.5 End-user footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 11.6.5.1 Detailed list of key startup/SME players
    • 11.6.5.2 Competitive benchmarking of key emerging players/startups
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 COLOPLAST CORP.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
      • 12.1.1.3.2 Expansions
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 B. BRAUN SE
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Key strengths
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses & competitive threats
  • 12.1.3 JOHNSON & JOHNSON SERVICES, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 MnM view
      • 12.1.3.3.1 Key strengths
      • 12.1.3.3.2 Strategic choices
      • 12.1.3.3.3 Weaknesses & competitive threats
  • 12.1.4 CONVATEC INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 BOSTON SCIENTIFIC CORPORATION
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 MEDTRONIC
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product approvals
  • 12.1.7 TELEFLEX INCORPORATED
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 BECTON, DICKINSON AND COMPANY (BD)
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
  • 12.1.9 CARDINAL HEALTH
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 HOLLISTER INCORPORATED
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches
  • 12.1.11 COOK GROUP
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 LABORIE
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Other developments
• 12.2 OTHER PLAYERS
  • 12.2.1 WELLSPECT HEALTHCARE
  • 12.2.2 CALDERA MEDICAL
  • 12.2.3 DYNAREX CORPORATION
  • 12.2.4 ADVACARE PHARMA
  • 12.2.5 MRK HEALTHCARE PVT. LTD.
  • 12.2.6 ADVIN HEALTH CARE
  • 12.2.7 CLINIMED LIMITED
  • 12.2.8 STERIMED GROUP
  • 12.2.9 KIMBERLY-CLARK CORPORATION (KCWW)
  • 12.2.10 INCONTROL MEDICAL
  • 12.2.11 ZEPHYR SURGICAL IMPLANTS
  • 12.2.12 FLEXICARE (GROUP) LIMITED
  • 12.2.13 STRYKER

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS